CoChat

Long-Term Efficacy of AAV9-U7snRNA-Mediated Exon 51 Skipping in mdx52 Mice

Aupy, Philippine, Zarrouki, Faouzi, Sandro, Quentin, Gastaldi, Cécile, Buclez, Pierre-Olivier, Mamchaoui, Kamel, Garcia, Luis, Vaillend, Cyrille, Goyenvalle, Aurélie · 2020 · Molecular Therapy - Methods & Clinical Development
Cited by 43

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.omtm.2020.04.025

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 35

  1. Koenig, 1989, The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion, Am. J. Hum. Genet., 45, 498
  2. Monaco, 1988, An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus, Genomics, 2, 90, 10.1016/0888-7543(88)90113-9 · DOI · Paper page
  3. Pramono, 1996, Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence, Biochem. Biophys. Res. Commun., 226, 445, 10.1006/bbrc.1996.1375 · DOI
  4. Dunckley, 1998, Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides, Hum. Mol. Genet., 7, 1083, 10.1093/hmg/7.7.1083 · DOI · Paper page
  5. Mann, 2001, Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse, Proc. Natl. Acad. Sci. USA, 98, 42, 10.1073/pnas.98.1.42 · DOI · Paper page
  6. Aartsma-Rus, 2006, Therapeutic modulation of DMD splicing by blocking exonic splicing enhancer sites with antisense oligonucleotides, Ann. N Y Acad. Sci., 1082, 74, 10.1196/annals.1348.058 · DOI
  7. Echevarría, 2018, Exon-skipping advances for Duchenne muscular dystrophy, Hum. Mol. Genet., 27, R163, 10.1093/hmg/ddy171 · DOI
  8. Crudele, 2019, AAV-based gene therapies for the muscular dystrophies, Hum. Mol. Genet., 28, R102, 10.1093/hmg/ddz128 · DOI · Paper page
  9. Goyenvalle, 2004, Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping, Science, 306, 1796, 10.1126/science.1104297 · DOI · Paper page
  10. Schümperli, 2004, The special Sm core structure of the U7 snRNP: far-reaching significance of a small nuclear ribonucleoprotein, Cell. Mol. Life Sci., 61, 2560, 10.1007/s00018-004-4190-0 · DOI
  11. Goyenvalle, 2012, Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping, Hum. Mol. Genet., 21, 2559, 10.1093/hmg/dds082 · DOI
  12. Goyenvalle, 2012, Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy, Mol. Ther., 20, 1212, 10.1038/mt.2012.26 · DOI
  13. Vulin, 2012, Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping, Mol. Ther., 20, 2120, 10.1038/mt.2012.181 · DOI
  14. Aartsma-Rus, 2009, Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations, Hum. Mutat., 30, 293, 10.1002/humu.20918 · DOI · Paper page
  15. Araki, 1997, Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy, Biochem. Biophys. Res. Commun., 238, 492, 10.1006/bbrc.1997.7328 · DOI · Paper page
  16. Bremmer-Bout, 2004, Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides, Mol. Ther., 10, 232, 10.1016/j.ymthe.2004.05.031 · DOI
  17. ’t Hoen, 2008, Generation and characterization of transgenic mice with the full-length human DMD gene, J. Biol. Chem., 283, 5899, 10.1074/jbc.M709410200 · DOI
  18. Zincarelli, 2010, Comparative cardiac gene delivery of adeno-associated virus serotypes 1–9 reveals that AAV6 mediates the most efficient transduction in mouse heart, Clin. Transl. Sci., 3, 81, 10.1111/j.1752-8062.2010.00190.x · DOI · Paper page
  19. Aoki, 2010, In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse, Mol. Ther., 18, 1995, 10.1038/mt.2010.186 · DOI
  20. Sekiguchi, 2009, A deficit of brain dystrophin impairs specific amygdala GABAergic transmission and enhances defensive behaviour in mice, Brain, 132, 124, 10.1093/brain/awn253 · DOI · Paper page
  21. Vaillend, 2017, Relationships linking emotional, motor, cognitive and GABAergic dysfunctions in dystrophin-deficient mdx mice, Hum. Mol. Genet., 26, 1041
  22. Yamamoto, 2010, Reduction of abnormal behavioral response to brief restraint by information from other mice in dystrophin-deficient mdx mice, Neuromuscul. Disord., 20, 505, 10.1016/j.nmd.2010.05.006 · DOI · Paper page
  23. Helleringer, 2018, Cerebellar synapse properties and cerebellum-dependent motor and non-motor performance in Dp71-null mice, Dis. Model. Mech., 11, 10.1242/dmm.033258 · DOI · Paper page
  24. Rouillon, 2015, Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies, Hum. Mol. Genet., 24, 4916, 10.1093/hmg/ddv214 · DOI
  25. Relizani, 2017, Efficacy and safety profile of tricyclo-DNA antisense oligonucleotides in Duchenne muscular dystrophy mouse model, Mol. Ther. Nucleic Acids, 8, 144, 10.1016/j.omtn.2017.06.013 · DOI · Paper page
  26. Spitali, 2013, DMD transcript imbalance determines dystrophin levels, FASEB J., 27, 4909, 10.1096/fj.13-232025 · DOI · Paper page
  27. Ruszczak, 2009, Differential stabilities of alternative exon-skipped rod motifs of dystrophin, Biochim. Biophys. Acta, 1794, 921, 10.1016/j.bbapap.2009.02.016 · DOI
  28. Sahni, 2012, Exon edited dystrophin rods in the hinge 3 region, Biochim. Biophys. Acta, 1824, 1080, 10.1016/j.bbapap.2012.06.011 · doi:10.1016/j.bbapap.2012.06.011
  29. McCourt, 2015, In vitro stability of therapeutically relevant, internally truncated dystrophins, Skelet. Muscle, 5, 13, 10.1186/s13395-015-0040-z · DOI
  30. Beggs, 1991, Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies, Am. J. Hum. Genet., 49, 54
  31. Carsana, 2005, Analysis of dystrophin gene deletions indicates that the hinge III region of the protein correlates with disease severity, Ann. Hum. Genet., 69, 253, 10.1046/J.1469-1809.2005.00160.x · doi:10.1046/j.1469-1809.2005.00160.x
  32. Goyenvalle, 2015, Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers, Nat. Med., 21, 270, 10.1038/nm.3765 · DOI · Paper page
  33. Le Hir, 2013, AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy, Mol. Ther., 21, 1551, 10.1038/mt.2013.121 · DOI · Paper page
  34. Dias Florencio, 2015, Simple downstream process based on detergent treatment improves yield and in vivo transduction efficacy of adeno-associated virus vectors, Mol. Ther. Methods Clin. Dev., 2, 15024, 10.1038/mtm.2015.24 · DOI · Paper page
  35. Aruga, 2004, Locomotor and oculomotor impairment associated with cerebellar dysgenesis in Zic3-deficient (Bent tail) mutant mice, Eur. J. Neurosci., 20, 2159, 10.1111/j.1460-9568.2004.03666.x · DOI

Cited by

See all 43

Metadata

Authors
Aupy, P., Zarrouki, F., Sandro, Q., Gastaldi, C., Buclez, P.-O., Mamchaoui, K., Garcia, L., Vaillend, C., & Goyenvalle, A.
Venue
Molecular Therapy - Methods & Clinical Development
Publisher
Elsevier BV
Published
2020-06
Volume
17
Pages
1037-1047
ISSN
2329-0501
Cited by
43
References
8
Language
en
Licence
Funders
  • Association Française contre les Myopathies
  • National Center of Neurology and Psychiatry
  • Agence Nationale de la Recherche
  • Institut National de la Santé et de la Recherche Médicale
  • Fondation pour la Recherche Médicale (PLP20161036676)
  • Centre National de la Recherche Scientifique
  • Duchenne Parent Project

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-Term Efficacy of AAV9-U7snRNA-Mediated Exon 51 Skipping in mdx52 Mice. https://app.cochat.ai/papers/10.1016/j.omtm.2020.04.025
The paper
Aupy, P., Zarrouki, F., Sandro, Q., Gastaldi, C., Buclez, P.-O., Mamchaoui, K., Garcia, L., Vaillend, C., & Goyenvalle, A. (2020). Long-Term Efficacy of AAV9-U7snRNA-Mediated Exon 51 Skipping in mdx52 Mice. Molecular Therapy - Methods & Clinical Development. https://doi.org/10.1016/j.omtm.2020.04.025

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.